Treating osteosarcoma cells with CCR5, FAK, AKT or HIF-1α inhibitors reversed CCL4-mediated inhibition of miR-3927-3p expression, which suggests that CCL4 may increase integrin αvβ3 expression and cell migration by inhibiting miR-3927-3p synthesis via CCR5 and FAK/AKT/HIF-1α signaling (Figure 7A). The gene discussed is CCL4; the disease is osteosarcoma.